Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease

Journal of Thoracic Oncology

Volumn 10, Issue 1, 2015, Pages 156-163

  Hoffknecht, Petra ^a   Tufman, Amanda ^b   Wehler, Thomas ^c   Pelzer, Theo ^d   Wiewrodt, Rainer ^e   Schütz, Martin ^f   Serke, Monika ^g   Stöhlmacher Williams, Jan ^h   Märten, Angela ⁱ   Huber, Rudolf Maria ^b   Dickgreber, Nicolas J ^a  

^a Department of Pneumology   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f Abteilung für Handchirurgie   (Germany)

^g LUNGENKLINIK HEMER   (Germany)

^h Private ENT Clinic   (Germany)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Afatinib; Central nervous system metastasis; Compassionate use program; ErbB family blocker; Non small cell lung cancer

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; GENE MUTATION; HUMAN; LEPTOMENINGEAL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SKIN TOXICITY; TIME TO TREATMENT; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; DISEASE COURSE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; MUTATION; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84926416449     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000380     Document Type: Article

References (51)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
2. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
3. Doroshow JH. Targeting EGFR in non-small-cell lung cancer. N Engl J Med 2005;353:200-202.
4. Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005;65:7525-7529.
5. Pao W. Defining clinically relevant molecular subsets of lung cancer. Cancer Chemother Pharmacol 2006;58(Suppl 1):s11-s15.
6. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
9. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
10. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
11. Pao W, Balak MN, Riely GJ, et al. Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol 2006;24(Suppl 18):7078.
12. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-2596.
13. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
14. Lynch TJ, Adjei AA, Bunn PA Jr, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006;12(14 Pt 2):4365s-4371s.
15. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
16. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-350.
17. Hsiao SH, Chung CL, Chou YT, et al. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer 2013;82:319-323.
18. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-7858.
19. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-7101.
20. Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol 2004;2:405-410.
21. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007;12:325-330.
22. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;48:384-394.
23. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-898.
24. Fan Y, Huang Z, Fang L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther 2013;6:1789-1803.
25. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24:1295-1304.
26. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207-6219.
27. Ruderman NB, Hall TC. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 1965;18:298-306.
28. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-191.
29. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010;12:1193-1199.
30. Hirsch FR, Jänne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013;8:373-384.
31. Miller VA, Hirsh V, Cadranel J, et al. Phase IIb/III double-blind randomized trial of afatinib (BIBW2992), an irreversible inhibitor of EGFR/Her1 and Her2 plus best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Ann Oncol 2010;21:LBA1.
32. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-538.
33. European Medicines Agency. Guideline on bioanalytical method validation. 2011; Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf. Accessed April 7, 2014.
34. Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2013; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf. Accessed April 7, 2014.
35. Schuler M, Fischer JR, Grohé C, et al. Experience with afatinib in patients with non-small-cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist 2014;19:1100-9.
36. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010;5:950-955.
37. Park JH, Kim YJ, Lee JO, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-392.
38. Berger LA, Riesenberg H, Bokemeyer C, et al. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 2013;80:242-248.
39. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009;65:351-354.
40. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line - is there a difference? J Clin Oncol 2013;31:1081-1088.
41. Dropcho EJ. Neurotoxicity of radiation therapy. Neurol Clin 2010;28:217-234.
42. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010;116:1336-1343.
43. Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 2013;52:1101-1109.
44. Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery 2014;4:1146-61.
45. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
46. Fukuhara T, Saijo Y, Sakakibara T, et al. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 2008;214:359-363.
47. Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011;67:1465-1469.
48. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a nonsmall-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-4520.
49. Dhruva N, Socinski MA. Carcinomatous meningitis in nonsmall-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009;27:e31-e32.
50. Hata A, Kaji R, Fujita S, et al. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. JThorac Oncol 2011;6:653-4.
51. Jackman DM, Mach SL, Heng JC, et al. Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2013;31:8116.